NEW
YORK, May 28, 2024 /PRNewswire/ -- Immunic,
Inc. (Nasdaq: IMUX), a biotechnology company
developing a clinical pipeline of orally administered, small
molecule therapies for chronic inflammatory and autoimmune
diseases, today announced participation in the following industry
and scientific conferences in June:
- June 3-6: BIO International
Convention 2024. Jessica Breu,
Vice President Investor Relations and Communications of Immunic,
will present a company overview on Tuesday,
June 4, 2024, at 11:00 am PDT
in Theater 1, at this conference in San
Diego, California. The presentation will be accessible on
the "Events and Presentations" section of Immunic's website at:
https://ir.imux.com/events-and-presentations. An archived replay
will be available after the conference.
Members of Immunic's management, business development and investor
relations teams will participate in partnering activities. To
schedule a meeting, please use the BIO International Convention
partnering portal.
- June 5-7: Pharmaceutical
Contract Management Group (PCMG) Assembly 2024. Werner
Gladdines, Vice President, Program Management & Clinical
Development Operations of Immunic, will participate in a panel
discussion at this assembly in Den Haag,
The Netherlands.
- Panel: Spin the Wheel of Collaboration!
- Date: Thursday, June 6,
2024
- Time: 12:05 pm CEST
About Immunic, Inc.
Immunic, Inc. (Nasdaq: IMUX) is a biotechnology company developing
a clinical pipeline of orally administered, small molecule
therapies for chronic inflammatory and autoimmune diseases. The
company's lead development program, vidofludimus calcium (IMU-838),
is currently in phase 3 and phase 2 clinical trials for the
treatment of relapsing and progressive multiple sclerosis,
respectively, and has shown therapeutic activity in phase 2
clinical trials in patients suffering from relapsing-remitting
multiple sclerosis, progressive multiple sclerosis and
moderate-to-severe ulcerative colitis. Vidofludimus calcium
combines neuroprotective effects, through its mechanism as a
first-in-class nuclear receptor related 1 (Nurr1) activator, with
additional anti-inflammatory and anti-viral effects, by selectively
inhibiting the enzyme dihydroorotate dehydrogenase (DHODH).
IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended
to restore intestinal barrier function and regenerate bowel
epithelium, which could potentially be applicable in numerous
gastrointestinal diseases, such as celiac disease, for which it is
currently in preparations for a phase 2 clinical trial. IMU-381,
which currently is in preclinical testing, is a next generation
molecule being developed to specifically address the needs of
gastrointestinal diseases. For further information, please visit:
www.imux.com.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains "forward-looking statements" that
involve substantial risks and uncertainties for purposes of the
safe harbor provided by the Private Securities Litigation Reform
Act of 1995. All statements, other than statements of historical
facts, included in this press release regarding strategy, future
operations, future financial position, future revenue, projected
expenses, sufficiency of cash, expected timing, development and
results of clinical trials, prospects, plans and objectives of
management are forward-looking statements. Examples of such
statements include, but are not limited to, statements relating to
management's and employee's participation in industry and
scientific conferences. Immunic may not actually
achieve the plans, carry out the intentions or meet the
expectations or projections disclosed in the forward-looking
statements and you should not place undue reliance on these
forward-looking statements. Such statements are based on
management's current expectations and involve substantial risks and
uncertainties. Actual results and performance could differ
materially from those projected in the forward-looking statements
as a result of many factors, including, without limitation, the
COVID-19 pandemic, increasing inflation, impacts of the
Ukraine – Russia conflict and the conflict in the
Middle East on planned and ongoing
clinical trials, risks and uncertainties associated with the
ability to project future cash utilization and reserves needed for
contingent future liabilities and business operations, the
availability of sufficient financial and other resources to meet
business objectives and operational requirements, the fact that the
results of earlier preclinical studies and clinical trials may not
be predictive of future clinical trial results, the protection and
market exclusivity provided by Immunic's intellectual
property, risks related to the drug development and the regulatory
approval process and the impact of competitive products and
technological changes. A further list and descriptions of these
risks, uncertainties and other factors can be found in the section
captioned "Risk Factors," in the company's Annual Report on Form
10-K for the fiscal year ended December 31,
2023, filed with the SEC on February
22, 2024, and in the company's subsequent filings with the
Securities and Exchange Commission. Copies of these filings are
available online at www.sec.gov or
ir.imux.com/sec-filings. Any forward-looking statement made
in this release speaks only as of the date of this release.
Immunic disclaims any intent or obligation to update these
forward-looking statements to reflect events or circumstances that
exist after the date on which they were made. Immunic
expressly disclaims all liability in respect to actions taken
or not taken based on any or all the contents of this press
release.
Contact Information
Immunic, Inc.
Jessica Breu
Vice President Investor Relations and Communications
+49 89 2080 477 09
jessica.breu@imux.com
US IR Contact
Rx Communications Group
Paula Schwartz
+1 917 633 7790
immunic@rxir.com
US Media Contact
KOGS Communication
Edna Kaplan
+1 617 974 8659
kaplan@kogspr.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/immunic-to-participate-in-industry-and-scientific-conferences-in-june-302156368.html
SOURCE Immunic, Inc.
